Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

16.73 +0.79 (+4.96%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
S&P 500, Nasdaq Extend Record Highs; Dow Up Triple Digits
The Dow Jones Industrial Average is up triple digits midday, as investors look ahead to this week's inflation data. 
Via Talk Markets
Topics Economy Stocks
Exposures Interest Rates US Equities
Corning Increases Sales Forecast, Joins Morphic Holding, Lucid Group And Other Big Stocks Moving Higher On Monday
Via Benzinga
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q1 2024
Pulse Biosciences just reported results for the first quarter of 2024. 
Via InvestorPlace
PLSE Stock Earnings: Pulse Biosciences Reported Results for Q4 2023
Pulse Biosciences just reported results for the fourth quarter of 2023. 
Via InvestorPlace
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Why SentinelOne Shares Are Trading Lower By 16%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Enhances Executive Leadership Team
From Pulse Biosciences, Inc.
Via Business Wire
Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Why Nuvve Holding Shares Are Trading Lower By Around 30%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Nuvve Holding Corp. (NASDAQ: NVVE) fell sharply during Monday’s session after the company reported worse-than-expected fourth-quarter financial results. 
Via Benzinga
Oxford Industries, PVH And 3 Stocks To Watch Heading Into Monday
With U.S. stock futures trading higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Plans to Initiate a Rights Offering
From Pulse Biosciences, Inc.
Via Business Wire
Earnings Scheduled For March 28, 2024
Companies Reporting Before The Bell • Universal Stainless (NASDAQ:USAP) is expected to report quarterly earnings at $0.32 per share on revenue of $78.65 million. 
Via Benzinga
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
From Pulse Biosciences, Inc.
Via Business Wire
Why Mesoblast Shares Are Trading Higher By 13%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Mesoblast Limited (NASDAQ: MESO) rose sharply during Monday’s session after the company announced FDA support of an accelerated approval pathway for rexlemestrocel-L in end-stage heart... 
Via Benzinga
Exposures Product Safety
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
From Pulse Biosciences, Inc.
Via Business Wire
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
From Pulse Biosciences, Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.